LONDON--(BUSINESSWIRE)--
The world is currently witnessing a growing interest in both cost savings and greater safety and efficacy associated with a personalized medicine approach to drug therapies. Considerable gains will be realized if the right drug can be given to the right patient at the right dose, within any therapeutic area. Though the reimbursement, pricing, coding, and regulatory systems that will support this scientific and clinical paradigm shift are still evolving, slowly but there are real revenues being made and real potential for earnings. Forecasts say the market will approach USD37,480 million by 2016 globally.
New research study World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing) worked out by Kalorama Information highlights the current opportunity and a realistic future potential for personalized medicine in clinical testing. Besides analyzing tests currently on the market and in development, it profiles key competitors and discusses trends important for understanding this growth area of the diagnostic industry. A special focus of the report is the bustle of activity with collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs.
Biomarkers discussed in the report include: Cytochrome P450 and Drug Metabolism, Estrogen Receptor and Progesterone, Receptor Status for Breast Cancer, HER2 Overexpression and Herceptin and Tykerb, Epidermal Growth Factor Receptor (EGFR), KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer, BRAF Mutations and Cancer Therapy, UGT1A1 Genetic Variants, 5-Flurouracil Therapy, PIK3CA Genetic Variation, KIF6 Genetic Variation, ALK Genetic Variation.
Report Details:
Title: World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
Published: March, 2011
Pages: 430
Price: US$ 3,795
Go here to read the rest:
Global Personalized Medicine Diagnostics Market Analyzed in New Study Now Available at MarketPublishers.com